Larvol Delta - Phase-1-Study-of-GCC2005-an-Allogeneic-CD5Directed-CARNK-Therapy-for-Patients-with-RelapsedRefractory-NKTcell-Malignancies

GCC2005 - Artiva Biotherapeutics

https://www.icksh.org/program/program.php

Dok Hyun Yoon

Mar 11, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next